NOW FDA APPROVED

See our press release

© 2025 Abeona Therapeutics Inc. All rights reserved. US-COM-ZEV-250033 03/25

Contact Us Careers
Facebook Twitter LinkedIn
logo_abeona_retina
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers
×
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers

Press Releases

Investors

Investors & Media

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Events
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Scientific Advisory Board
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Events
  • Email Alerts

Abeona Therapeutics Enrolls 5th Patient in Phase 1/2 Gene Therapy Clinical Trial for Epidermolysis Bullosa

Sep 8, 2016

Abeona Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

Sep 7, 2016

Abeona Therapeutics to Present at Landmark Angels 6th Annual Investing for Cures 2016 Conference

Sep 1, 2016

Abeona Therapeutics Completes Enrollment of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients

Aug 29, 2016

Abeona Therapeutics Announces Second Quarter 2016 Financial Results and Recent Clinical Highlights

Aug 16, 2016

Abeona Therapeutics, EB Research Partnership and EB Medical Research Foundation to Collaborate on Epidermolysis Bullosa (EB) Treatments

Aug 9, 2016

Abeona Therapeutics Announces European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Aug 4, 2016

Abeona Therapeutics Provides Update on Initial Subjects in Sanfilippo Type A Gene Therapy Trial, Demonstrating Encouraging Early Biopotency Signals

Aug 2, 2016

Abeona Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

Jun 30, 2016

Abeona Therapeutics to Present at Jefferies 2016 Global Healthcare Conference

Jun 7, 2016
RSS
    • 1...
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31

    © 2025 Abeona Therapeutics Inc. All Rights Reserved. | Privacy Policy Terms of Use